BIOHEART-B published IBERIS-HTN research results in CIRCULATION
BIOHEART-B announced that the research results of Iberis-HTN have been published in "Circulation." The study evaluated the safety and efficacy of a novel multi-electrode radiofrequency renal denervation system in Chinese patients with hypertension. The results showed that RDN is safe in patients whose hypertension remains uncontrolled after standardized triple drug therapy and can effectively reduce both ambulatory blood pressure and office blood pressure. The company's CEO, Wang Li, stated that they look forward to providing safer and more effective renal sympathetic denervation treatments for patients worldwide
According to the Zhitong Finance APP, BIOHEART-B (02185) announced that the results of the Iberis-HTN study, titled "Efficacy and safety of catheter-based radiofrequency renal denervation in Chinese patients with uncontrolled hypertension: the randomized, sham-controlled, multi-center Iberis-HTN trial," have been published in Circulation. The Iberis-HTN study is a key trial for our RDN product, the Iberis renal nerve ablation system, conducted in China.
Renal nerve denervation (RDN) can reduce blood pressure in patients with hypertension, both with and without drug treatment. Iberis-HTN is a sham-controlled trial conducted in China aimed at assessing the safety and efficacy of a novel multi-electrode radiofrequency RDN catheter system in patients whose hypertension remains uncontrolled after standardized triple drug therapy. This study shows that RDN is safe in this trial involving Chinese patients whose hypertension remains uncontrolled after standardized triple drug therapy, and it can reduce ambulatory blood pressure and office blood pressure compared to the sham control group over a period of 6 months.
Professor Jiang Xiongjing and Professor Felix Mahfoud made equal contributions to this publication and are co-first authors, while Academician Gao Runlin is the corresponding author.
The company's founder and CEO, Wang Li, stated: "We are pleased to see our Iberis-HTN trial results published in Circulation. This is also our first trial published that includes the renal nerve ablation procedure performed via the transradial approach (TRA). TRA makes RDN safer, more effective, and more cost-effective. Our ultimate goal is to provide outpatient treatment for renal sympathetic nerve ablation to patients worldwide."
